1.1.2
Home The syllabus Cards How lessons are made
Sign up free Log in

1.1.2 · Allergy and Immunology · Anaphylaxis

Aspirin idiosyncrasy: NSAID hypersensitivity and what is safe

<2% of the exam 6 min

What the exam asks

From the history, which kind of NSAID reaction this is; whether another NSAID, acetaminophen or a COX-2 inhibitor is safe; how the diagnosis is confirmed; and what to do when the patient needs aspirin (coronary disease, a stent). ABIM's tasks here: diagnosis, recommending treatment, the mechanism behind the answer.

The one-minute version

  • "Aspirin idiosyncrasy" is the old name for NSAID hypersensitivity; most reactions are cross-reactive, driven by COX-1 inhibition, not by IgE1.
  • Cross-reactive patients react to every strong COX-1 inhibitor but almost always tolerate selective COX-2 inhibitors12.
  • A reaction to a single NSAID is immunologic: avoid that drug and its chemical group; unrelated NSAIDs are tolerated1.
  • Acetaminophen is a weak COX-1 inhibitor: doses of 1000 mg or more can trigger reactions in sensitive patients3.
  • An oral challenge confirms the type; when aspirin is needed, desensitize and give it every day24.

Name the pattern

About 80% of adverse reactions to NSAIDs are predictable pharmacologic (type A) effects such as bleeding or dyspepsia; hypersensitivity is the minority5.

Type Who Reaction
NSAID-exacerbated respiratory disease (N-ERD, AERD) Asthma and/or chronic rhinosinusitis with nasal polyps Nasal congestion, rhinorrhea, bronchospasm within hours1
NSAID-exacerbated cutaneous disease (NECD) Chronic spontaneous urticaria Flare of urticaria or angioedema1
NSAID-induced urticaria, angioedema or anaphylaxis (NIUAA) Otherwise healthy Reactions to two or more chemically unrelated NSAIDs1
Single NSAID-induced (SNIUAA) Anyone Urticaria, angioedema or anaphylaxis to one NSAID or its chemical group1

The first three are cross-reactive; the last is selective1.

Evidence: the sources' own words
  • 5 The majority (around 80%) of ADR to NSAID are pharmacological and predictable (type A)
  • 1 the NIUA type refers to reactions to ≥2 NSAIDs belonging to different chemical groups
  • 1 develop immediate reactions to a single NSAID or closely related drugs from the same chemical group, but tolerate other, non-chemically related NSAIDs
  • 1 Nasal airway congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm

Why it happens

COX-1 makes prostaglandin E2, which restrains inflammatory cells; blocking COX-1 removes that brake, and susceptible patients already make too little protective PGE21. That is why the reaction follows the drug's COX-1 potency, not its chemistry, and why selective COX-2 inhibitors are spared1.

A single-NSAID reaction is different: it is independent of COX-1 strength and points to a specific immune (IgE) mechanism1.

Evidence: the sources' own words
  • 1 PGE2 exerts anti-inflammatory effects while PGD2 is a potent bronchoconstrictor
  • 1 reduced production of protective PGE2
  • 1 patients with N-ERD almost always tolerate selective COX-2 inhibitors during observed drug challenges
  • 1 The reaction is independent of the strength of COX-1 inhibition, pointing to a probable specific immunological mechanism

What is safe

  • Cross-reactive types: avoid every NSAID with strong COX-1 activity; a selective COX-2 inhibitor can be used when an anti-inflammatory is needed2. In 3218 blinded challenges with selective COX-2 inhibitors, 3.3% reacted1.
  • Acetaminophen: 34% of aspirin-sensitive asthmatics reacted to 1000 to 1500 mg, usually mildly; avoid 1000 mg or more3.
  • Selective type: avoid the culprit and its chemical group; chemically unrelated NSAIDs are tolerated1.
  • Analgesia without testing: opioids act by a different mechanism and can be used5.
Evidence: the sources' own words
  • 2 the patient is prompted to avoid all NSAIDs with strong COX-1 inhibitory activity, but selective COX-2 inhibitors can be recommended if anti-inflammatory treatment is indicated
  • 1 a total of 3218 single- or double-blinded placebo-controlled DCs with selective COX-2 inhibitors, 106 (3.3%) of which caused reactions
  • 3 17 of 50 (34%) of aspirin-sensitive asthmatic patients reacted to acetaminophen in doses of 1000 to 1500 mg
  • 3 high doses of acetaminophen (1000 mg or greater) should be avoided in aspirin-sensitive asthmatic patients
  • 1 but tolerate other, non-chemically related NSAIDs
  • 5 opiates can be recommended as safe alternatives for analgesia even without testing

Confirm it

  • The oral challenge is the gold standard: challenge with aspirin (or another strong COX-1 inhibitor if aspirin was the culprit); a reaction confirms a cross-reactive type, tolerance points to a selective one2.
  • Reading it: tolerating 325 mg of aspirin without upper or lower airway symptoms generally excludes COX-1 hypersensitivity1.
  • Safety first: the patient must be stable with FEV1 at least 70% of predicted, and must not be taking a beta-blocker1.
  • No blood test is reliable for N-ERD1.
Evidence: the sources' own words
  • 2 If a patient previously reacted to NSADs other than aspirin, oral challenge with aspirin is the gold standard.
  • 1 Tolerance of 325 mg of ASA during a graded DC without upper or lower reaction symptoms generally excludes COX-1 inhibitor hypersensitivity.
  • 1 with an FEV1 ≥ 70% of predicted value
  • 1 Current treatment with β-blockers is contraindicated in patients referred to the DC.
  • 1 No in vitro tests are sensitive or reliable to be recommended in the diagnosis of N-ERD.

When aspirin is needed

  • Desensitization gives rising doses until a full dose is tolerated; the dose must then be taken every day, and a pause of more than about 48 hours loses the effect54.
  • Acute coronary syndrome with a stent: EAACI recommends aspirin desensitization for patients who need dual antiplatelet therapy; in NSTEMI it is done before angiography4.
  • STEMI: primary PCI comes first with an IV antiplatelet bridge, then desensitization within 12 to 72 hours4.
Evidence: the sources' own words
  • 5 a maximum pause of only 48 h is permitted, otherwise the desensitization effect is lost
  • 4 patients should take aspirin every day to perpetuate the temporary clinical unresponsiveness to it
  • 4 aspirin desensitization is recommended in all such patients with ACS requiring DAPT after coronary stenting
  • 4 aspirin desensitization should be performed prior to coronary angiography
  • 4 within 12–72 h, aspirin desensitization can be performed with the normal regimen

Board traps

  • "Switch from ibuprofen to naproxen." In a cross-reactive patient every strong COX-1 inhibitor cross-reacts, whatever its chemical class2.
  • "Acetaminophen 1 g is safe." A third of aspirin-sensitive asthmatics reacted at 1000 to 1500 mg3.
  • "Avoid aspirin for good after an ACS in a patient labelled allergic." Labels are often wrong (a third of those labelled had only gastrointestinal symptoms), and desensitization is the standard when dual antiplatelet therapy is needed4.
Evidence: the sources' own words
  • 2 avoid all NSAIDs with strong COX-1 inhibitory activity
  • 3 17 of 50 (34%) of aspirin-sensitive asthmatic patients reacted
  • 4 69 patients (32.2%) who reported gastrointestinal symptoms were incorrectly labeled as “allergic”
  • 4 aspirin desensitization is recommended in all such patients with ACS requiring DAPT after coronary stenting

Europe differs

The US (AAAAI/ACAAI) and European (EAACI/ENDA) systems name the same types but draw the line between immediate and delayed reactions differently: 6 hours in the US, 24 hours in Europe; the respiratory type is "AERD" in the US and "N-ERD" in Europe1.

Evidence: the sources' own words
  • 1 Immediate reactions occur within hours (≤6 h2,3 or ≤ 24 h1) of exposure

Think it through

A 46-year-old woman with asthma and two operations for nasal polyps develops nasal congestion and wheeze 40 minutes after ibuprofen 400 mg for knee pain. Her asthma is now controlled. Her knee osteoarthritis needs an anti-inflammatory drug.

Which drug is most appropriate?

Show the answer

A selective COX-2 inhibitor such as celecoxib, ideally with the first dose under observation. Asthma, nasal polyps and a respiratory reaction to an NSAID make this N-ERD, a cross-reactive type: all strong COX-1 inhibitors (naproxen, diclofenac, aspirin) are off the list2, while patients with N-ERD almost always tolerate selective COX-2 inhibitors in observed challenges1. Acetaminophen at 1000 mg or more is not a safe default here3.

Evidence: the sources' own words
  • 2 selective COX-2 inhibitors can be recommended if anti-inflammatory treatment is indicated
  • 1 patients with N-ERD almost always tolerate selective COX-2 inhibitors during observed drug challenges
  • 3 high doses of acetaminophen (1000 mg or greater) should be avoided in aspirin-sensitive asthmatic patients

References

Every claim above carries its number. Records come from PubMed; the evidence lines quote each source's own words.

  1. 1.

    Romano A, Valluzzi RL, Alvarez-Cuesta E, et al. Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement. World Allergy Organ J 2025.

    review PMID 40837856 DOI 10.1016/j.waojou.2025.101086 PMC12361610 Read: full text

    Open access, CC BY 4.0

  2. 2.

    Kowalski ML, Makowska JS Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? Allergy Asthma Immunol Res 2015.

    review PMID 25749768 DOI 10.4168/aair.2015.7.4.312 PMC4446629 Read: full text

    Open access, CC BY-NC

  3. 3.

    Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995.

    trial PMID 7560658 DOI 10.1016/s0091-6749(95)70290-3 Read: abstract

    Not open access: cited and paraphrased, abstract read; no text reproduced beyond short evidence quotes.

  4. 4.

    Cortellini G, Nakonechna A, Barbaud A, et al. Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. Allergy 2025.

    consensus PMID 40704552 DOI 10.1111/all.16663 PMC12590344 Read: full text

    Open access, CC BY-NC-ND

  5. 5.

    Wöhrl S NSAID hypersensitivity - recommendations for diagnostic work up and patient management. Allergo J Int 2018.

    review PMID 29974031 DOI 10.1007/s40629-018-0064-0 PMC6004000 Read: full text

    Open access, CC BY 4.0

Flashcards

9 cards check what this lesson taught.

Practise them now. With a free account they also come back for review when you are about to forget them.